The ethics of psychopharmacological research in legal minors

被引：14

作者：

Tan J.O.A. ^{[1
]}

Koelch M. ^{[2
]}

机构：

[1] Ethox Centre, University of Oxford, Oxford OX3 7LF, Old Road Campus, Headington

[2] Department of Child and Adolescent Psychiatry/Psychotherapy, University Hospital Ulm, Ulm

来源：

Child and Adolescent Psychiatry and Mental Health | / 2卷 / 1期

基金：

英国惠康基金;

关键词：

Minimal Risk; Ethical Dilemma; Adolescent Psychiatry; Research Participation; Ethical Analysis;

D O I：

10.1186/1753-2000-2-39

中图分类号：

学科分类号：

摘要：

Research in psychopharmacology for children and adolescents is fraught with ethical problems and tensions. This has practical consequences as it leads to a paucity of the research that is essential to support the treatment of this vulnerable group. In this article, we will discuss some of the ethical issues which are relevant to such research, and explore their implications for both research and standard care. We suggest that finding a way forward requires a willingness to acknowledge and discuss the inherent conflicts between the ethical principles involved. Furthermore, in order to facilitate more, ethically sound psychopharmacology research in children and adolescents, we suggest more ethical analysis, empirical ethics research and ethics input built into psychopharmacological research design. © 2008 Tan and Koelch; licensee BioMed Central Ltd.

引用

共 61 条

[1]

Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, 1964, (2000)

[2]

Bakker M.K., Kolling P., Berg P.B., de Walle H.E., de Jong van den Berg L.T., Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands, Br J Clin Pharmacol, 65, pp. 600-606, (2008)

[3]

Conroy S., Choonara I., Impicciatore P., Mohn A., Arnell H., Rane A., Knoeppel C., Seyberth H., Pandolfini C., Raffaelli M.P., Et al., Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children, Bmj, 320, pp. 79-82, (2000)

[4]

Horen B., Montastruc J.L., Lapeyre-Mestre M., Adverse drug reactions and off-label drug use in paediatric outpatients, Br J Clin Pharmacol, 54, pp. 665-670, (2002)

[5]

Waller D.G., Off-label and unlicensed prescribing for children: Have we made any progress?, Br J Clin Pharmacol, 64, pp. 1-2, (2007)

[6]

Dell M.L., Vaughan B.S., Kratochvil C.J., Ethics and the prescription pad, Child Adolesc Psychiatr Clin N Am, 17, pp. 93-111, (2008)

[7]

Volkers A.C., Heerdink E.R., van Dijk L., Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005), Pharmacoepidemiol Drug Saf, 16, pp. 1054-1062, (2007)

[8]

Zito J.M., Safer D.J., Valluri S., Gardner J.F., Korelitz J.J., Mattison D.R., Psychotherapeutic medication prevalence in Medicaid-insured preschoolers, J Child Adolesc Psychopharmacol, 17, pp. 195-203, (2007)

[9]

Schepker R., Lippert H.-D., Kolch M., Fegert J., Fragwürdigkeit eines Gerichtsurteils zur Antidepressiva- Verordnung bei Jugendlichen/The dilemma of court expertise- commentary on the SSRI- tapering verdict by the saxonian social court, Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie, 35, pp. 207-212, (2007)

[10]

Fegert J.M., Ethical and Legal Problems in Treating Schizophrenic Patients with Neuroleptics During Childhood and Adolescence, Child and Adolescent Psychopharmacology News, 8, (2003)

← 1 2 3 4 5 6 7 →